Fat, fire and muscle - The role of adiponectin in pulmonary vascular inflammation and remodeling

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 4, 2013, Pages 420-426

  Medoff, Benjamin D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adiponectin; Obesity; Pulmonary hypertension; Pulmonary vascular disease

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; FAT;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; BLOOD VESSEL TONE; BODY MASS; CELL PROLIFERATION; HUMAN; LUNG BLOOD VESSEL; NONHUMAN; OBESITY; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULITIS; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER;

ADIPOCYTES; ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; MICE; OBESITY; RISK FACTORS;

EID: 84880514990     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2012.06.006     Document Type: Article

References (112)

1. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. NEngl J Med 2004, 351:1655-1665.
2. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010, 121:2045-2066.
3. Daley E., Emson C., Guignabert C., de Waal Malefyt R., Louten J., Kurup V.P., et al. Pulmonary arterial remodeling induced by a Th2 immune response. JExp Med 2008, 205:361-372.
4. Hansmann G., Rabinovitch M. The protective role of adiponectin in pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 2010, 298:L1-L2.
5. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. JClin Invest 2008, 118:2372-2379.
6. Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L. Prevalence and trends in obesity among US adults, 1999-2000. JAm Med Assoc 2002, 288:1723-1727.
7. Beuther D.A., Sutherland E.R. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007, 175:661-666.
8. Beuther D.A., Weiss S.T., Sutherland E.R. Obesity and asthma. Am J Respir Crit Care Med 2006, 174:112-119.
9. Parameswaran K., Todd D.C., Soth M. Altered respiratory physiology in obesity. Can Respir J 2006, 13:203-210.
10. Sztrymf B., Ioos V., Sitbon O., Parent F., Simonneau G., Humbert M. Pulmonary hypertension and obesity. Revue de Pneumologie Clinique 2002, 58:104-110.
11. Tilg H., Moschen A.R. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006, 6:772-783.
12. Burger C.D., Foreman A.J., Miller D.P., Safford R.E., McGoon M.D., Badesch D.B. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. Mayo Clin Proc 2011, 86:105-112.
13. Haque A.K., Gadre S., Taylor J., Haque S.A., Freeman D., Duarte A. Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects. Arch Pathol Lab Med 2008, 132:1397-1404.
14. Krenning G., Moonen J.R., Harmsen M.C. Pleiotropism of adiponectin: inflammation, neovascularization, and fibrosis. Circ Res 2009, 104:1029-1031.
15. Okamoto Y., Kihara S., Funahashi T., Matsuzawa Y., Libby P. Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278.
16. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
17. Waki H., Yamauchi T., Kamon J., Ito Y., Uchida S., Kita S., et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. JBiol Chem 2003, 278:40352-40363.
18. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
19. Ryo M., Nakamura T., Kihara S., Kumada M., Shibazaki S., Takahashi M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68:975-981.
20. Kumada M., Kihara S., Sumitsuji S., Kawamoto T., Matsumoto S., Ouchi N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
21. Nakamura Y., Shimada K., Fukuda D., Shimada Y., Ehara S., Hirose M., et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004, 90:528-533.
22. Iwashima Y., Horio T., Suzuki Y., Kihara S., Rakugi H., Kangawa K., et al. Adiponectin and inflammatory markers in peripheral arterial occlusive disease. Atherosclerosis 2006, 188:384-390.
23. Iwashima Y., Katsuya T., Ishikawa K., Ouchi N., Ohishi M., Sugimoto K., et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 2004, 43:1318-1323.
24. Pischon T., Girman C.J., Hotamisligil G.S., Rifai N., Hu F.B., Rimm E.B. Plasma adiponectin levels and risk of myocardial infarction in men. JAm Med Assoc 2004, 291:1730-1737.
25. Maeda N., Takahashi M., Funahashi T., Kihara S., Nishizawa H., Kishida K., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50:2094-2099.
26. Neschen S., Morino K., Rossbacher J.C., Pongratz R.L., Cline G.W., Sono S., et al. Fish oil regulates adiponectin secretion by a peroxisome proliferator-activated receptor-gamma-dependent mechanism in mice. Diabetes 2006, 55:924-928.
27. Takemura Y., Walsh K., Ouchi N. Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep 2007, 9:238-243.
28. Fantuzzi G. Adiponectin and inflammation: consensus and controversy. JAllergy Clin Immunol 2008, 121:326-330.
29. Sam F., Walsh K. What can adiponectin say about left ventricular function?. Heart 2010, 96:331-332.
30. Turner J.J., Smolinska M.J., Sacre S.M., Foxwell B.M. Induction of TLR tolerance in human macrophages by adiponectin: does LPS play a role?. Scand J Immunol 2009, 69:329-336.
31. Maeda N., Shimomura I., Kishida K., Nishizawa H., Matsuda M., Nagaretani H., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
32. Nawrocki A.R., Rajala M.W., Tomas E., Pajvani U.B., Saha A.K., Trumbauer M.E., et al. Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor gamma agonists. JBiol Chem 2006, 281:2654-2660.
33. Kim J.Y., van de Wall E., Laplante M., Azzara A., Trujillo M.E., Hofmann S.M., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. JClin Invest 2007, 117:2621-2637.
34. Shibata R., Sato K., Pimentel D.R., Takemura Y., Kihara S., Ohashi K., et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005, 11:1096-1103.
35. Shibata R., Ouchi N., Ito M., Kihara S., Shiojima I., Pimentel D.R., et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med 2004, 10:1384-1389.
36. Liao Y., Takashima S., Maeda N., Ouchi N., Komamura K., Shimomura I., et al. Exacerbation of heart failure in adiponectin-deficient mice due to impaired regulation of AMPK and glucose metabolism. Cardiovasc Res 2005, 67:705-713.
37. Shibata R., Izumiya Y., Sato K., Papanicolaou K., Kihara S., Colucci W.S., et al. Adiponectin protects against the development of systolic dysfunction following myocardial infarction. JMol Cell Cardiol 2007, 42:1065-1074.
38. Ohashi K., Kihara S., Ouchi N., Kumada M., Fujita K., Hiuge A., et al. Adiponectin replenishment ameliorates obesity-related hypertension. Hypertension 2006, 47:1108-1116.
39. Shibata R., Ouchi N., Kihara S., Sato K., Funahashi T., Walsh K. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of amp-activated protein kinase signaling. JBiol Chem 2004, 279:28670-28674.
40. Kondo M., Shibata R., Miura R., Shimano M., Kondo K., Li P., et al. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of endothelial nitric-oxide synthase. JBiol Chem 2009, 284:1718-1724.
41. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
42. Ohashi K., Parker J.L., Ouchi N., Higuchi A., Vita J.A., Gokce N., et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. JBiol Chem 2010, 285:6153-6160.
43. Ouchi N., Kobayashi H., Kihara S., Kumada M., Sato K., Inoue T., et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. JBiol Chem 2004, 279:1304-1309.
44. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang Cc C., Itani S.I., et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002, 99:16309-16313.
45. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
46. Yamauchi T., Nio Y., Maki T., Kobayashi M., Takazawa T., Iwabu M., et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007, 13:332-339.
47. Denzel M.S., Hebbard L.W., Shostak G., Shapiro L., Cardiff R.D., Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. Clin Cancer Res 2009, 15:3256-3264.
48. Denzel M.S., Scimia M.C., Zumstein P.M., Walsh K., Ruiz-Lozano P., Ranscht B. T-cadherin is critical for adiponectin-mediated cardioprotection in mice. JClin Invest 2010, 120:4342-4352.
49. Takemura Y., Ouchi N., Shibata R., Aprahamian T., Kirber M.T., Summer R.S., et al. Adiponectin modulates inflammatory reactions via calreticulin receptor-dependent clearance of early apoptotic bodies. JClin Invest 2007, 117:375-386.
50. Matsuda M., Shimomura I., Sata M., Arita Y., Nishida M., Maeda N., et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. JBiol Chem 2002, 277:37487-37491.
51. Medoff B.D., Okamoto Y., Leyton P., Weng M., Sandall B.P., Raher M.J., et al. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 2009, 41:397-406.
52. Weng M., Raher M.J., Leyton P., Combs T.P., Scherer P.E., Bloch K.D., et al. Adiponectin decreases pulmonary arterial remodeling in mouse models of pulmonary hypertension. Am J Respir Cell Mol Biol 2010.
53. Humbert M., Monti G., Brenot F., Sitbon O., Portier A., Grangeot-Keros L., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995, 151:1628-1631.
54. Fartoukh M., Emilie D., Le Gall C., Monti G., Simonneau G., Humbert M. Chemokine macrophage inflammatory protein-1alpha mRNA expression in lung biopsy specimens of primary pulmonary hypertension. Chest 1998, 114:50S-51S.
55. Dorfmuller P., Humbert M., Perros F., Sanchez O., Simonneau G., Muller K.M., et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007, 38:893-902.
56. Nicolls M.R., Taraseviciene-Stewart L., Rai P.R., Badesch D.B., Voelkel N.F. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005, 26:1110-1118.
57. Tuder R.M., Groves B., Badesch D.B., Voelkel N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994, 144:275-285.
58. Soon E., Holmes A.M., Treacy C.M., Doughty N.J., Southgate L., Machado R.D., et al. Elevated levels of inflammatory cytokines predict survival in idiopathicandfamilial pulmonary arterial hypertension. Circulation 2010, 122:920-927.
59. Morrell N.W., Adnot S., Archer S.L., Dupuis J., Jones P.L., MacLean M.R., et al. Cellular and molecular basis of pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54:S20-S31.
60. Hassoun P.M., Mouthon L., Barbera J.A., Eddahibi S., Flores S.C., Grimminger F., et al. Inflammation, growth factors, and pulmonary vascular remodeling. JAm Coll Cardiol 2009, 54:S10-S19.
61. Tormanen K.R., Uller L., Persson C.G., Erjefalt J.S. Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels. Am J Respir Crit Care Med 2005, 171:19-25.
62. Rydell-Tormanen K., Uller L., Erjefalt J.S. Remodeling of extra-bronchial lungvasculature following allergic airway inflammation. Respir Res 2008, 9:18.
63. Rydell-Tormanen K., Johnson J.R., Fattouh R., Jordana M., Erjefalt J.S. Induction of vascular remodeling in the lung by chronic house dust mite exposure. Am J Respir Cell Mol Biol 2008, 39:61-67.
64. Steiner M.K., Syrkina O.L., Kolliputi N., Mark E.J., Hales C.A., Waxman A.B. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009, 104:236-244. 28p following 44.
65. Summer R., Fiack C.A., Ikeda Y., Sato K., Dwyer D., Ouchi N., et al. Adiponectin deficiency: a model of pulmonary hypertension associated with pulmonary vascular disease. Am J Physiol Lung Cell Mol Physiol 2009, 297:L432-L438.
66. Weng M., Baron D.M., Bloch K.D., Luster A.D., Lee J.J., Medoff B.D. Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2011, 301:L927-L936.
67. Song H., Chan J., Rovin B.H. Induction of chemokine expression by adiponectin invitro is isoform dependent. Transl Res 2009, 154:18-26.
68. Robinson K., Prins J., Venkatesh B. Clinical review: adiponectin biology and its role in inflammation and critical illness. Crit Care 2011, 15:221.
69. Yamaguchi N., Argueta J.G., Masuhiro Y., Kagishita M., Nonaka K., Saito T., et al. Adiponectin inhibits Toll-like receptor family-induced signaling. FEBS Lett 2005, 579:6821-6826.
70. Wolf A.M., Wolf D., Rumpold H., Enrich B., Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun 2004, 323:630-635.
71. Yokota T., Oritani K., Takahashi I., Ishikawa J., Matsuyama A., Ouchi N., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
72. Lovren F., Pan Y., Quan A., Szmitko P.E., Singh K.K., Shukla P.C., et al. Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol 2010, 299:H656-H663.
73. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
74. Kobashi C., Urakaze M., Kishida M., Kibayashi E., Kobayashi H., Kihara S., et al. Adiponectin inhibits endothelial synthesis of interleukin-8. Circ Res 2005, 97:1245-1252.
75. Ouedraogo R., Gong Y., Berzins B., Wu X., Mahadev K., Hough K., et al. Adiponectin deficiency increases leukocyte-endothelium interactions via upregulation of endothelial cell adhesion molecules invivo. JClin Invest 2007, 117:1718-1726.
76. Masaie H., Oritani K., Yokota T., Takahashi I., Shirogane T., Ujiie H., et al. Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates. Exp Hematol 2007, 35:947-956.
77. Wang Y., Lam K.S., Xu J.Y., Lu G., Xu L.Y., Cooper G.J., et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. JBiol Chem 2005, 280:18341-18347.
78. Davie N.J., Crossno J.T., Frid M.G., Hofmeister S.E., Reeves J.T., Hyde D.M., et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol 2004, 286:L668-L678.
79. Frid M.G., Kale V.A., Stenmark K.R. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: invitro analysis. Circ Res 2002, 90:1189-1196.
80. Balasubramaniam V., Le Cras T.D., Ivy D.D., Grover T.R., Kinsella J.P., Abman S.H. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003, 284:L826-L833.
81. Christou H., Yoshida A., Arthur V., Morita T., Kourembanas S. Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1998, 18:768-776.
82. Partovian C., Adnot S., Raffestin B., Louzier V., Levame M., Mavier I.M., et al. Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000, 23:762-771.
83. Perros F., Montani D., Dorfmuller P., Durand-Gasselin I., Tcherakian C., Le Pavec J., et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008, 178:81-88.
84. Schermuly R.T., Dony E., Ghofrani H.A., Pullamsetti S., Savai R., Roth M., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. JClin Invest 2005, 115:2811-2821.
85. Ding M., Xie Y., Wagner R.J., Jin Y., Carrao A.C., Liu L.S., et al. Adiponectin induces vascular smooth muscle cell differentiation via repression of mammalian target of rapamycin complex 1 and FoxO4. Arterioscler Thromb Vasc Biol 2011, 31:1403-1410.
86. Arita Y., Kihara S., Ouchi N., Maeda K., Kuriyama H., Okamoto Y., et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002, 105:2893-2898.
87. Weng M., Raher M.J., Leyton P., Combs T.P., Scherer P.E., Bloch K.D., et al. Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. Am J Respir Cell Mol Biol 2011, 45:340-347.
88. Rzucidlo E.M., Martin K.A., Powell R.J. Regulation of vascular smooth muscle cell differentiation. JVasc Surg 2007, 45(Suppl. A):A25-A32.
89. Motoshima H., Goldstein B.J., Igata M., Araki E. AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. JPhysiol 2006, 574:63-71.
90. Krymskaya V.P. Targeting the phosphatidylinositol 3-kinase pathway inairway smooth muscle: rationale and promise. BioDrugs 2007, 21:85-95.
91. Wang C., Mao X., Wang L., Liu M., Wetzel M.D., Guan K.L., et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1. JBiol Chem 2007, 282:7991-7996.
92. Jeffery P.K. Remodeling and inflammation of bronchi in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2004, 1:176-183.
93. Gizycki M.J., Adelroth E., Rogers A.V., O'Byrne P.M., Jeffery P.K. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma. Am J Respir Cell Mol Biol 1997, 16:664-673.
94. Kumar M.S., Owens G.K. Combinatorial control of smooth muscle-specific gene expression. Arterioscler Thromb Vasc Biol 2003, 23:737-747.
95. Owens G.K., Kumar M.S., Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 2004, 84:767-801.
96. Miano J.M. Serum response factor: toggling between disparate programs of gene expression. JMol Cell Cardiol 2003, 35:577-593.
97. Miano J.M., Long X., Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Physiol 2007, 292:C70-C81.
98. Posern G., Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol 2006, 16:588-596.
99. Arsenian S., Weinhold B., Oelgeschlager M., Ruther U., Nordheim A. Serum response factor is essential for mesoderm formation during mouse embryogenesis. Embo J 1998, 17:6289-6299.
100. Miano J.M., Ramanan N., Georger M.A., de Mesy Bentley K.L., Emerson R.L., Balza R.O., et al. Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci U S A 2004, 101:17132-17137.
101. Angstenberger M., Wegener J.W., Pichler B.J., Judenhofer M.S., Feil S., Alberti S., et al. Severe intestinal obstruction on induced smooth muscle-specific ablation of the transcription factor SRF in adult mice. Gastroenterology 2007, 133:1948-1959.
102. Mericskay M., Blanc J., Tritsch E., Moriez R., Aubert P., Neunlist M., et al. Inducible mouse model of chronic intestinal pseudo-obstruction by smooth muscle-specific inactivation of the SRF gene. Gastroenterology 2007, 133:1960-1970.
103. Li R., Wang W.Q., Zhang H., Yang X., Fan Q., Christopher T.A., et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab 2007, 293:E1703-E1708.
104. Schmid P.M., Resch M., Steege A., Fredersdorf-Hahn S., Stoelcker B., Birner C., et al. Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats. Am J Hypertens 2011, 24:270-277.
105. Gustafsson S., Lind L., Soderberg S., Ingelsson E. Associations of circulating adiponectin with measures of vascular function and morphology. JClin Endocrinol Metab 2010, 95:2927-2934.
106. Tan K.C., Xu A., Chow W.S., Lam M.C., Ai V.H., Tam S.C., et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. JClin Endocrinol Metab 2004, 89:765-769.
107. Hansmann G., Wagner R.A., Schellong S., Perez V.A., Urashima T., Wang L., et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007, 115:1275-1284.
108. Hansmann G., de Jesus Perez V.A., Alastalo T.P., Alvira C.M., Guignabert C., Bekker J.M., et al. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. JClin Invest 2008, 118:1846-1857.
109. Zamanian R.T., Hansmann G., Snook S., Lilienfeld D., Rappaport K.M., Reaven G.M., et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009, 33:318-324.
110. Shklyaev S., Aslanidi G., Tennant M., Prima V., Kohlbrenner E., Kroutov V., et al. Sustained peripheral expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci U S A 2003, 100:14217-14222.
111. Tao L., Wang Y., Gao E., Zhang H., Yuan Y., Lau W.B., et al. Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 2010, 106:409-417.
112. Badesch D.B., Raskob G.E., Elliott C.G., Krichman A.M., Farber H.W., Frost A.E., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry. Chest 2010, 137:376-387.